The Guardian view on Merck’s exit: Britain’s biopharma strategy stalls in the face of China’s rise | Editorial
NegativeFinancial Markets

Merck's recent decision to close its London research hub highlights significant concerns about the UK's support for the biopharma industry. Critics point to inadequate backing for life sciences and strict NHS drug pricing as key issues.
Editor’s Note: This situation is crucial as it reflects broader challenges in the UK's biopharma strategy, especially in the face of rising competition from China. The loss of Merck's investment could have long-term implications for innovation and job creation in the UK.
— Curated by the World Pulse Now AI Editorial System